Dillon PM, Petroni GR, Moskaluk C, Fracasso PM, Douvas MG, Perez JR, Varhegyi N, Zaja-Milatovic S, Thomas CY. A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC) [abstract]. J Clin Oncol. 2015;33(15 Suppl):e17092.
Hollen PJ, Gralla RJ, Jones RA, Thomas CY, Brenin DR, Weiss GR, Schroen AT, Petroni GR. A theory-based decision aid for patients with cancer: results of feasibility and acceptability testing of DecisionKEYS for cancer. Support Care Cancer. 2013;21(3):889-899.
Dillon PM, Moskaluk C, Fracasso PM, Petroni GR, Thomas CY. Phase II study of dovitinib (TK1258) in patients with progressive metastatic adenoid cystic carcinoma [abstract]. J Clin Oncol. 2013;31(15 Suppl):6021.
Glisson BS, Tseng J, Marur S, Shin DM, Murphy BA, Cohen EEW, Thomas CY, Willey R, Cosaert J, William WN, Harun N, Lee JJ, Haddad RI. Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN) [abstract]. J Clin Oncol. 2013;31(15 Suppl):6030.
Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, Wang Z, Zhang Z, Sun J, Sun J, Koty PP, Kader AK, Cramer SD, Bova GS, Zheng SL, Gronberg H, Isaacs WB, Xu J. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer. 2013;119(13):2405-2412.
Thomas CY, Hemal AK. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int. 2013;112(4):425-426.
Rahimi AS, Wilson DD, Saylor DK, Stelow EB, Thomas CY, Reibel JF, Levine PA, Shonka DC, Jameson MJ, Read PW. p16, Cyclin D1, and HIF-1alpha predict outcomes of patients with oropharyngeal squamous cell carcinoma treated with definitive intensity-modulated radiation therapy. Int J Otolaryngol. 2012;2012():685951.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
Associate Professor, Hematology & Oncology
Bladder Cancer, Genitourinary Cancer, Genitourinary Oncology, Prostate Cancer
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.
The provider provided plenty of time for me. He didn't seem rushed at all
Very good experience
I HAVE NEVER HAD A BAD EXPERIENCE.
*Dr. Thomas is a great doctor.
Wish I lived closer, would be my doctor for treatment.
*Dr. Thomas has always been helpful.
*Dr. Thomas respects the fact I am very informed and involved in my healthcare. He's an excellent provider.